La Merie Publishing is an independent business information provider for the biotechnology and pharmaceutical industry. We publish proprietary reports and prepare custom reports.
DLL3: competitors of clinically validated target develop effector-enhanced next generation product candidates STUTTGART, Germany I August 05, 2025 I La Merie Publishing released its newest product entitled: DLL3-Targeted Immunotherapy: a Competitor Analysis. DLL3 is a clinically validated target for treatment of small cell lung cancer which recently started commercialization. Delta-like canonical Notch ligand 3 (DLL3) […]
TSLP (thymic stromal lymphoprotein) is a clinically and commercially validated inflammatory target attracting numerous competitors STUTTGART, Germany I August 05, 2025 I La Merie Publishing released its newest product entitled: TSLP Inhibitors and TSLP Receptor Antagonists: a Competitor Analysis TSLP inhibitor Tezspire clinically has validated Thymic Stromal LymphoPoietin (TSLP) as a valid target for treatment […]
TL1A (TNF-like ligand 1A): the next big, clinically validated target for inflammatory bowel disease STUTTGART, Germany I August 05, 2025 I La Merie Publishing released its newest product entitled: TL1A Inhibitors & DR3 Antagonists: a Competitor Analysis TL1A as a target for mainly inflammatory bowel disease recently has received great interest from major pharmaceutical companies […]
Folate Receptor alpha: a clinically validated target for ovarian cancer with commercial potential and a decent competitive environment STUTTGART, Germany I August 05, 2025 I La Merie Publishing released its newest product entitled: Folate Receptor alpha (FRα) Targeted Therapy: a Competitor Analysis Folate receptor alpha (FRα) is a cell surface GPI-anchored protein overexpressed in several […]
Fibroblast Activation Protein: an emerging high-value theranostic target for delivery of payloads STUTTGART, Germany I August 05, 2025 I La Merie Publishing released its newest product entitled: Fibroblast Activation Protein (FAP) Targeted Therapy: a Competitor Analysis. Fibroblast activation protein (FAP) is selectively expressed in reactive stromal fibroblasts of epithelial cancers, granulation tissue of healing wounds, […]
Glypican-3 (GPC3): an emerging liver cancer target with opportunities for different effector mechanisms STUTTGART, Germany I August 05, 2025 I La Merie Publishing released its newest product entitled: Glypican-3 (GPC3) Targeted Therapy: a Competitor Analysis. GPC3, a GPI-anchored cell surface heparan sulfate proteoglycan, is an attractive target for hepatocellular carcinoma (HCC) immunotherapy because it is […]
B7-H3: an emerging solid tumor target with promise for antibody-drug conjugates STUTTGART, Germany I August 05, 2025 I La Merie Publishing released its newest product entitled: B7-H3-Targeted Immunotherapy: a Competitor Analysis. B7-H3 is a transmembrane protein that belongs to the B7 family, which also includes PD-L1. B7-H3 is overexpressed in a wide range of cancer […]
STUTTGART, Germany I June 28, 2025 I Vectorized antibodies obtained by in vivo expression of DNA or RNA are an emerging drug modality with potential to overcome several of the limitations of passive immunotherapy with antibodies produced ex vivo. La Merie Publishing released a new report about gene therapy technologies for in vivo expression of […]
The report covers 2024 sales data of innovator therapeutic antibodies and proteins, biosimilars and the novel biologic drug modalities gene & cell therapy and RNA products STUTTGART, Germany I March 09, 2025 I La Merie Publishing announced the release of its newest biologics market report for the calendar year 2024 covering individual sales data for […]
STUTTGART, Germany I February 19, 2025 I La Merie Publishing released its newest report with a landscape description and analysis of PD-1 x VEGF and PD-L1 x VEGF bispecific antibodies regarding stakeholders, R&D pipeline, clinical profile and molecular structure of drug candidates and business deals from an industry perspective as of February 2025: PD-1 x […]
